HAGOP M KANTARJIAN

TitleProfessor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM, Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024 Feb 27; 8(4):927-935. PMID: 38113472; PMCID: PMC10877112.
      Citations:    Fields:    Translation:Humans
    2. Short NJ, Jabbour EJ, Jain N, Senapati J, Nasr LF, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian HM, Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2024 Feb 27; 8(4):909-915. PMID: 38207208; PMCID: PMC10875259.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    3. Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024 Feb 23. PMID: 38400519.
      Citations:    Fields:    
    4. Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol. 2024 Feb 15. PMID: 38361282.
      Citations:    Fields:    
    5. Dinh A, Savoy JM, Kontoyiannis DP, Takahashi K, Issa GC, Kantarjian HM, DiNardo CD, Rausch CR. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2024 Feb 10. PMID: 38340331.
      Citations:    Fields:    
    6. Jabbour E, Zugmaier G, Agrawal V, Mart?nez-S?nchez P, Rif?n Roca JJ, Cassaday RD, B?ll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, D?az MT, Vucinic V, Gonz?lez-Campos J, Rambaldi A, Schwartz S, Berthon C, Hern?ndez-Rivas JM, Gordon PR, Br?ggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 Feb 05. PMID: 38317420.
      Citations:    Fields:    
    7. Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Feb 02. PMID: 38316133.
      Citations:    Fields:    
    8. Haddad FG, Kantarjian H. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw. 2024 Feb; 22(1). PMID: 38394773.
      Citations:    Fields:    
    9. Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax. Clin Cancer Res. 2024 Feb 01. PMID: 38300723.
      Citations:    Fields:    
    10. Jabbour EJ, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen JL, Wang SA, Alvarado Y, Wang X, DiNardo CD, Masarova L, Kadia TM, Garris R, Ravandi F, Kantarjian HM, Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421. PMID: 37879077.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    11. Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J, Rosti G, Rousselot P, Shah NP, Talpaz M, Vorog A, Ren X, Kantarjian H. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Jan 29. PMID: 38287132.
      Citations:    Fields:    
    12. Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol. 2024 Jan 26; JCO2301911. PMID: 38277619.
      Citations:    Fields:    
    13. Roboz GJ, Sanz GF, Griffiths EA, Yee KWL, Kantarjian HM, R?cher C, Byrne MT, Patkowska E, Kim HJ, Thomas X, Moors I, Stock W, Illes A, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell C, Hao Y, Keer HN, Azab M, D?hner H. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 Jan 17. PMID: 38231126.
      Citations:    Fields:    
    14. Kantarjian HM, Jabbour EJ, Lipton JH, Castagnetti F, Br?mmendorf TH. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jan 12. PMID: 38278737.
      Citations:    Fields:    
    15. Senapati J, Kantarjian H, Haddad FG, Short NJ, Welch MA, Jain N, Jabbour E. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jan 08. PMID: 38195323.
      Citations:    Fields:    
    16. Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26. PMID: 38135371.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    17. Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica. 2024 Jan 01; 109(1):293-297. PMID: 37646654; PMCID: PMC10772528.
      Citations:    Fields:    Translation:Humans
    18. Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2023 Dec 30. PMID: 38212207.
      Citations:    Fields:    
    19. Kantarjian H, Zeidan AM, Fathi AT, Stein E, Rajkumar V, Tefferi A. Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective. Mayo Clin Proc. 2024 Jan; 99(1):15-21. PMID: 38108685.
      Citations:    Fields:    Translation:Humans
    20. Haddad FG, Jabbour E, Short NJ, Jain N, Kantarjian H. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2023 Dec 14. PMID: 38185587.
      Citations:    Fields:    
    21. Birdwell CE, Fiskus W, Kadia TM, Mill CP, Sasaki K, Daver N, DiNardo CD, Pemmaraju N, Borthakur G, Davis JA, Das K, Sharma S, Horrigan S, Ruan X, Su X, Khoury JD, Kantarjian H, Bhalla KN. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2023 Dec 12. PMID: 38086946.
      Citations:    Fields:    
    22. Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips AH, Khoury J, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris RS, Nasr LF, Kriwacki RW, Roberts KG, Konopleva M, Jabbour EJ, Mullighan CG. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. medRxiv. 2023 Dec 09. PMID: 38106221; PMCID: PMC10723521.
      Citations:    
    23. Jen WY, Sasaki K, Rausch CR, DiNardo CD, Kadia TM, Yilmaz M, Borthakur G, Alvarado Y, McCue D, Mccue D, Kantarjian HM, Ravandi F, McCue D. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. Leuk Lymphoma. 2024 Mar; 65(3):378-382. PMID: 38054837.
      Citations:    Fields:    Translation:Humans
    24. Kantarjian H, Welch MA, Sasaki K. Early mortality after chemotherapy as a quality indicator-the leukemia perspective. Blood Cancer J. 2023 Dec 01; 13(1):176. PMID: 38040680; PMCID: PMC10692074.
      Citations:    Fields:    Translation:Humans
    25. Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, Yilmaz M, Kantarjian H, Odenike O, Patel A, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims A. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505. PMID: 37647601; PMCID: PMC10632668.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    26. Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. 2023 Nov 10. PMID: 37946611.
      Citations:    Fields:    
    27. Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023 11 09; 142(19):1647-1657. PMID: 37441846.
      Citations:    Fields:    
    28. Briski R, Garcia-Manero G, Kantarjian H, Ravandi F. The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia. Ther Adv Hematol. 2023; 14:20406207231205429. PMID: 37854355; PMCID: PMC10580721.
      Citations:    
    29. Kantarjian HM, Logan AC, Zaman F, G?kbuget N, Bargou RC, Zeng Y, Zugmaier G, Locatelli F. Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab. Ther Adv Hematol. 2023; 14:20406207231201454. PMID: 37822571; PMCID: PMC10563488.
      Citations:    
    30. Kantarjian HM. What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia. Leukemia. 2023 11; 37(11):2324-2325. PMID: 37798329.
      Citations:    Fields:    Translation:Humans
    31. Aminu M, Daver N, Godoy MCB, Shroff G, Wu C, Torre-Sada LF, Goizueta A, Shannon VR, Faiz SA, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim ST, Kontoyiannis DP, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Front Immunol. 2023; 14:1249511. PMID: 37841255; PMCID: PMC10570510.
      Citations:    Fields:    Translation:Humans
    32. Sasaki K, Haddad FG, Short NJ, Jain N, Issa G, Jabbour E, Kantarjian H. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer. 2023 12 01; 129(23):3805-3814. PMID: 37769040.
      Citations:    Fields:    Translation:HumansCells
    33. Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J. 2023 09 21; 13(1):148. PMID: 37735426; PMCID: PMC10514257.
      Citations:    Fields:    Translation:Humans
    34. Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 11 01; 41(31):4893-4904. PMID: 37703506; PMCID: PMC10617926.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    35. Fenaux P, Gobbi M, Kropf PL, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian H, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein J, Gercheva-Kyuchukova L, Demeter J, Griffiths E, Yee K, D?hner K, Hao Y, Keer H, Azab M, D?hner H. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood Adv. 2023 09 12; 7(17):5027-5037. PMID: 37276510; PMCID: PMC10471926.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    36. Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek S, Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek S. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol. 2023; 146(6):522-529. PMID: 37699357.
      Citations:    Fields:    Translation:Humans
    37. Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023 Nov; 98(11):1780-1790. PMID: 37665752.
      Citations: 2     Fields:    
    38. Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. 2023 09 01; 108(9):2331-2342. PMID: 36951163; PMCID: PMC10483357.
      Citations: 2     Fields:    Translation:Humans
    39. Kantarjian HM, Welch MA, Jabbour E. Revisiting six established practices in the treatment of chronic myeloid leukaemia. Lancet Haematol. 2023 Oct; 10(10):e860-e864. PMID: 37652074.
      Citations: 1     Fields:    
    40. Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720. PMID: 37635400.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    41. Sasaki K, Ravandi F, DiNardo C, Welch MA, Kadia T, Kantarjian H. Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2023 Dec; 23(12):905-910. PMID: 37730483.
      Citations: 1     Fields:    Translation:Humans
    42. Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2023 11; 203(4):581-592. PMID: 37608562.
      Citations:    Fields:    Translation:Humans
    43. Sasaki K, Morita K, Kantarjian H, Garcia-Manero G, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver N, Takahashi K, DiNardo C, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS, Cortes JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):e369-e378. PMID: 37690903.
      Citations:    Fields:    Translation:Humans
    44. Locatelli F, Shah B, Thomas T, Velasco K, Adedokun B, Aldoss I, Gore L, Hoelzer D, Bassan R, Park JH, Boissel N, Kantarjian H. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review. Leuk Lymphoma. 2023 10; 64(10):1615-1633. PMID: 37526512.
      Citations:    Fields:    
    45. Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol. 2023 10; 98(10):E281-E284. PMID: 37515433.
      Citations:    Fields:    Translation:Humans
    46. Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023 07 25; 7(14):3573-3581. PMID: 37104058; PMCID: PMC10368841.
      Citations:    Fields:    Translation:Humans
    47. Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023 10; 98(10):1619-1626. PMID: 37485584.
      Citations:    Fields:    Translation:Humans
    48. Mi YC, Zhu HH, Qin YZ, Zhang ZL, Liu YJ, Wen LJ, You MJ, Zhang C, Such E, Luo H, Yuan HJ, Zhou HS, Liu HX, Xu R, Li J, Li JH, Hao JP, Jin J, Yu L, Zhang JY, Liu LP, Zhang LP, Huang RB, Shen SH, Gao SJ, Wang W, Yan XJ, Zhang XY, Du X, Chu XX, Yu YF, Wang Y, Lu Y, Cai Z, Su Z, Taussig DC, MacMahon S, Ball ED, Wang HY, Welch JS, Yin CC, Borthakur G, Sanz MA, Kantarjian HM, Huang JY, Hu J, Chen SN. A global study for acute myeloid leukemia with RARG rearrangement. Blood Adv. 2023 07 11; 7(13):2972-2982. PMID: 36799929; PMCID: PMC10320208.
      Citations: 1     Fields:    Translation:Humans
    49. Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296. PMID: 36884300; PMCID: PMC10336257.
      Citations:    Fields:    Translation:Humans
    50. Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023 07 08; 16(1):73. PMID: 37422688; PMCID: PMC10329789.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    51. Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov. 2023 07 05; 4(4):276-293. PMID: 37102976; PMCID: PMC10320628.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    52. Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101. PMID: 37386016; PMCID: PMC10310786.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    53. Kantarjian HM, Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress. Am J Hematol. 2023 09; 98(9):1350-1353. PMID: 37357837.
      Citations:    Fields:    Translation:Humans
    54. Horst HA, Zugmaier G, Martinelli G, Mergen N, Velasco K, Zaman F, Kantarjian H. CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis. Am J Hematol. 2023 08; 98(8):E222-E225. PMID: 37345570.
      Citations:    Fields:    Translation:Humans
    55. Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023 09; 98(9):1383-1393. PMID: 37334870.
      Citations:    Fields:    Translation:Humans
    56. DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 2023 06 13; 7(11):2378-2387. PMID: 35973199; PMCID: PMC10220255.
      Citations:    
    57. Bhattacharya S, Piya S, Ma H, Sharma P, Zhang Q, Baran N, Ruvolo VR, McQueen T, Davis RE, Pourebrahim R, Konopleva M, Kantarjian H, Cosford NDP, Andreeff M, Borthakur G. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia. Mol Cancer Res. 2023 06 01; 21(6):548-563. PMID: 36787422.
      Citations:    Fields:    Translation:Animals
    58. Radich JP, Wall M, Branford S, Campbell CD, Chaturvedi S, DeAngelo DJ, Deininger M, Guinney J, Hochhaus A, Hughes TP, Kantarjian HM, Larson RA, Li S, Maegawa R, Mishra K, Obourn V, Pinilla-Ibarz J, Purkayastha D, Sadek I, Saglio G, Shrestha A, White BS, Druker BJ. Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. 2023 06 01; 108(6):1567-1578. PMID: 36727397; PMCID: PMC10230428.
      Citations: 1     Fields:    Translation:Humans
    59. Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer. 2023 09 15; 129(18):2828-2835. PMID: 37243913.
      Citations: 1     Fields:    Translation:Humans
    60. Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, Borthakur G, Alvarado Y, Garcia-Manero G, Jabbour E, Kantarjian H. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):742-748. PMID: 37308342.
      Citations:    Fields:    Translation:Humans
    61. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966. PMID: 36287248; PMCID: PMC10189379.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    62. Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023 08; 98(8):1196-1203. PMID: 37183966.
      Citations:    Fields:    Translation:Humans
    63. Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444. PMID: 37187201.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    64. Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023 05 02; 16(1):44. PMID: 37131217; PMCID: PMC10155451.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    65. Pemmaraju N, Kantarjian H. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clin Adv Hematol Oncol. 2023 May; 21(5):257-264. PMID: 37145496.
      Citations: 1     Fields:    Translation:HumansCells
    66. Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol. 2023 05; 7:e2200707. PMID: 37196217; PMCID: PMC10309573.
      Citations:    Fields:    Translation:HumansCells
    67. Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia. 2023 06; 37(6):1397-1400. PMID: 37185307.
      Citations:    Fields:    Translation:HumansCells
    68. Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023 04 24; 13(1):58. PMID: 37088793; PMCID: PMC10123066.
      Citations: 6     Fields:    Translation:Humans
    69. Montalban-Bravo G, Ma F, Thongon N, Yang H, Gomez IG, Rodriguez-Sevilla JJ, Adema V, Wildeman B, Lockyer P, Kim YJ, Tanaka T, Darbaniyan F, Pancholy S, Zhang G, Al-Atrash G, Dwyer K, Takahashi K, Garcia-Manero G, Kantarjian H, Colla S. Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia. bioRxiv. 2023 Apr 08. PMID: 37066354; PMCID: PMC10104149.
      Citations:    
    70. Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, Roboz GJ, Sweet K, Miller C, Wennborg A, Hickman DK, Kanagal-Shamanna R, Kantarjian H, Lancet J, Komrokji R, Attar EC, Sallman DA. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023 Apr; 10(4):e272-e283. PMID: 36990622.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    71. Short NJ, Kantarjian H. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematol. 2023 May; 10(5):e382-e388. PMID: 37003279.
      Citations: 1     Fields:    Translation:Humans
    72. Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. 2023 06; 37(6):1336-1348. PMID: 36977823; PMCID: PMC10244173.
      Citations:    Fields:    Translation:Humans
    73. Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023 03 28; 7(6):933-942. PMID: 36322818; PMCID: PMC10027507.
      Citations: 6     Fields:    Translation:Humans
    74. Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol. 2023 05; 201(3):e25-e29. PMID: 36951293.
      Citations:    Fields:    Translation:Humans
    75. Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 06; 98(6):E142-E144. PMID: 36877196.
      Citations:    Fields:    Translation:Humans
    76. Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023 03 16; 16(1):22. PMID: 36927623; PMCID: PMC10018889.
      Citations: 4     Fields:    Translation:HumansCells
    77. Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023 03; 615(7954):920-924. PMID: 36922593; PMCID: PMC10060155.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    78. Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer. 2023 06 15; 129(12):1856-1865. PMID: 36892949.
      Citations:    Fields:    Translation:Humans
    79. Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023 05 20; 41(15):2815-2826. PMID: 36888930; PMCID: PMC10414740.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    80. Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer. 2023 06 15; 129(12):1866-1872. PMID: 36882573.
      Citations:    Fields:    Translation:Humans
    81. Queudeville M, Stein AS, Locatelli F, Ebinger M, Handgretinger R, G?kbuget N, Gore L, Zeng Y, Gokani P, Zugmaier G, Kantarjian HM. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2023 05 01; 129(9):1384-1393. PMID: 36829303.
      Citations: 1     Fields:    Translation:Humans
    82. Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578. PMID: 36399715.
      Citations: 3     Fields:    Translation:HumansCells
    83. Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. Am J Hematol. 2023 04; 98(4):E91-E94. PMID: 36661399.
      Citations:    Fields:    Translation:Humans
    84. Sawyers JD, Jammal NJ, Short NJ, Kantarjian H, Jabbour EJ. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2023 Feb; 21(2):68-75. PMID: 36780472.
      Citations:    Fields:    Translation:HumansCells
    85. Rausch CR, Kantarjian HM, Jabbour EJ. SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches. Clin Lymphoma Myeloma Leuk. 2023 04; 23(4):238-243. PMID: 36872149.
      Citations:    Fields:    Translation:Humans
    86. Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023 04; 98(4):658-665. PMID: 36683287.
      Citations: 1     Fields:    Translation:Humans
    87. Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer. 2023 04 01; 129(7):1017-1029. PMID: 36715486.
      Citations: 1     Fields:    Translation:Humans
    88. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126. PMID: 36658425.
      Citations: 28     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    89. Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H. Chronic myeloid leukemia without major molecular response after 2?years of treatment with tyrosine kinase inhibitor. Am J Hematol. 2023 04; 98(4):639-644. PMID: 36606715.
      Citations: 4     Fields:    Translation:Humans
    90. Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 03; 98(3):493-501. PMID: 36600670.
      Citations: 1     Fields:    Translation:HumansCells
    91. Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56. PMID: 36565294.
      Citations: 1     Fields:    Translation:Humans
    92. Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 2023 02 15; 129(4):560-568. PMID: 36458426.
      Citations: 1     Fields:    Translation:Humans
    93. Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer. 2023 02 15; 129(4):580-589. PMID: 36448227.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    94. Bazinet A, Kantarjian HM. Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol. 2023 02; 34(2):141-151. PMID: 36423744.
      Citations: 3     Fields:    Translation:Humans
    95. Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, Jabbour E, Faramand R, Shah B, Locke F, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022 11 17; 140(20):2101-2112. PMID: 35877996; PMCID: PMC9837437.
      Citations:    Fields:    
    96. Shallis RM, Daver NG, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, Santini V, Wei AH, Sallman DA, Zeidan AM. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer. 2023 01 15; 129(2):175-180. PMID: 36397669.
      Citations: 3     Fields:    Translation:HumansCells
    97. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2022 Nov 16. PMID: 36402146.
      Citations: 13     Fields:    
    98. Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, Kantarjian HM. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022 11 02; 12(11):2516-2529. PMID: 36218325; PMCID: PMC9627130.
      Citations: 16     Fields:    Translation:Humans
    99. Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023 01; 37(1):5-17. PMID: 36309558.
      Citations: 4     Fields:    Translation:Humans
    100. Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, Sasaki K, Issa GC. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 2022 10 28; 12(10):144. PMID: 36307398; PMCID: PMC9616867.
      Citations: 5     Fields:    Translation:Humans
    101. Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022 Dec; 9(12):e878-e885. PMID: 36279879.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    102. Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022 10 20; 140(16):1753-1763. PMID: 35512188; PMCID: PMC9837415.
      Citations:    Fields:    
    103. Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022 Dec; 97(12):1599-1606. PMID: 36117258.
      Citations:    
    104. Short NJ, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Gonzalez GN, Hwang H, Qi X, Kantarjian H, Zhou S, Ravandi F. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 2022 12; 36(12):2817-2826. PMID: 36261575.
      Citations: 8     Fields:    Translation:Humans
    105. Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 Nov; 97(11):1427-1434. PMID: 36053747.
      Citations:    
    106. Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. 2022 Dec; 97(12):1560-1567. PMID: 36087091.
      Citations:    
    107. Kantarjian H, Paul S, Thakkar J, Jabbour E. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol. 2022 Nov; 9(11):e854-e861. PMID: 36174582.
      Citations: 2     Fields:    Translation:Humans
    108. Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, Stevens D, Kantarjian H, Traina F, Venditti A, Mayer J, Montez M, Jin H, Duan Y, Brackman D, Zha J, Potluri J, Werner M, Jonas BA. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol. 2022 Nov; 97(11):E416-E419. PMID: 36054316.
      Citations:    
    109. Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, Konopleva M, Ofran Y, Montesinos P, Kovacsovics T, Jang JH, Kantarjian H, Duan Y, Potluri J, Werner M, Pratz KW. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Am J Hematol. 2022 11; 97(11):E422-E425. PMID: 36053878; PMCID: PMC10286746.
      Citations:    
    110. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022 Nov; 97(11):1443-1452. PMID: 36054614.
      Citations:    
    111. Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease?(MRD) recurrence following MRD-negative remission. Am J Hematol. 2022 Nov; 97(11):E408-E411. PMID: 36054774.
      Citations:    
    112. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022 Oct; 9(10):e756-e765. PMID: 36063832.
      Citations:    
    113. Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. JAMA Oncol. 2022 09 01; 8(9):1340-1348. PMID: 35834222.
      Citations:    Fields:    
    114. Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, Chuah C, DeAngelo DJ, DiPersio J, Hochhaus A, Lipton J, Nicolini FE, Pinilla-Ibarz J, Rea D, Rosti G, Rousselot P, Shah NP, Talpaz M, Srivastava S, Ren X, Mauro M. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022 11; 97(11):1419-1426. PMID: 36054756; PMCID: PMC9804741.
      Citations:    
    115. Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022 Nov; 97(11):1413-1418. PMID: 36054032.
      Citations:    
    116. Short NJ, Kantarjian H. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions. Am J Hematol. 2022 Dec; 97(12):1616-1626. PMID: 35871436.
      Citations:    Fields:    
    117. Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do KA, Class C, Short NJ, Kanagal-Shamana R, Kadia T, Borthakur G, Pemmaraju N, Cortes J, Ravandi F, Alvarado Y, Chien K, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Soltysiak K, Yang H, Kantarjian HM, Garcia-Manero G. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid. 2022 Oct; 1(10):EVIDoa2200034. PMID: 38319837.
      Citations: 1     Translation:Humans
    118. Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, Kadia T, Chien K, Rush D, Nguyen H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Kantarjian H, Medeiros LJ, Luthra R, Kanagal-Shamanna R. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia. 2022 09; 36(9):2306-2316. PMID: 35915143; PMCID: PMC9417987.
      Citations:    
    119. Zeidan AM, Gobbi M, Roboz GJ, Robak T, Kantarjian HM, Jedrzejczak WW, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva L, Demeter J, Griffiths EA, Yee KWL, Issa JJ, Bewersdorf JP, Keer H, Hao Y, Azab M, Fenaux P, Mayer J, Krauter J, Nov?k J, Thomas X, Ojeda-Uribe M, D?hner H. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood. 2022 07 21; 140(3):285-289. PMID: 35507690; PMCID: PMC9305088.
      Citations:    Fields:    Translation:Humans
    120. Nichols ED, Jabbour E, Jammal N, Chew S, Bryan J, Issa G, Garcia-Manero G, Sasaki K, DiPippo A, Kantarjian H. Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. Am J Hematol. 2022 Sep; 97(9):E350-E352. PMID: 35759571.
      Citations:    Fields:    
    121. Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 09 10; 40(26):3032-3036. PMID: 35820082; PMCID: PMC9462530.
      Citations:    Fields:    
    122. Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014. PMID: 35533262; PMCID: PMC9278301.
      Citations:    Fields:    Translation:Humans
    123. Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins CA, Jabbour EJ, Medeiros LJ, Bhalla K, Kantarjian HM, Ravandi F, Khoury JD. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72. PMID: 35390143; PMCID: PMC9346958.
      Citations: 1     Fields:    Translation:Humans
    124. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022 Sep; 97(9):1236-1256. PMID: 35751859.
      Citations:    Fields:    
    125. Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma. 2022 11; 63(11):2701-2705. PMID: 35787095.
      Citations:    Fields:    
    126. Short NJ, Kantarjian H. Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia. Lancet Haematol. 2022 Jul; 9(7):e535-e545. PMID: 35772432.
      Citations:    Fields:    Translation:HumansCells
    127. Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, Kantarjian HM, DiNardo CD, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Wei AH. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Na?ve Acute Myeloid Leukemia. Clin Cancer Res. 2022 07 01; 28(13):2744-2752. PMID: 35063965.
      Citations: 1     Fields:    Translation:Humans
    128. Pollyea DA, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, Rizzieri DA, Smith BD, Shinagawa A, Lemoli RM, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Kantarjian HM. Impact of Venetoclax and Azacitidine in Treatment-Na?ve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clin Cancer Res. 2022 07 01; 28(13):2753-2761. PMID: 35046058.
      Citations: 2     Fields:    Translation:Humans
    129. Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022 Sep; 97(9):1135-1141. PMID: 35713551.
      Citations:    Fields:    
    130. Khoury JD, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Solary E, Berti E, Busque L, Colmenero I, Fontenay M, Germing U, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic?Neoplasms. Leukemia. 2022 07; 36(7):1703-1719. PMID: 35732831; PMCID: PMC9252913.
      Citations: 2     Fields:    Translation:Humans
    131. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 11 20; 40(33):3848-3857. PMID: 35704787; PMCID: PMC9671758.
      Citations:    Fields:    
    132. Paul S, Kantarjian H, Sasaki K, Marx K, Jain N, Savoy JM, DiPippo A, Jammal N, Bravo GM, Kadia T, Garcia-Manero G, Short NJ, Ravandi F, Jabbour E. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol. 2023 01; 98(1):E11-E14. PMID: 35633516.
      Citations:    Fields:    
    133. Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, Chang JY, Lin SH. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):977-988. PMID: 35675852.
      Citations:    Fields:    
    134. Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol. 2022 08; 97(8):1005-1012. PMID: 35567779; PMCID: PMC9354943.
      Citations:    Fields:    Translation:Humans
    135. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043. PMID: 35583199.
      Citations: 1     Fields:    Translation:Humans
    136. Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022 05 24; 6(10):3027-3035. PMID: 35061885; PMCID: PMC9131912.
      Citations: 1     Fields:    Translation:HumansCells
    137. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 05 02; 12(5):77. PMID: 35501304; PMCID: PMC9061716.
      Citations:    Fields:    Translation:Humans
    138. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022 May; 9(5):e350-e360. PMID: 35483396; PMCID: PMC9946440.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    139. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 May; 36(5):1448. PMID: 35411096.
      Citations:    Fields:    
    140. Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022 07; 97(7):885-894. PMID: 35413152.
      Citations:    Fields:    Translation:Humans
    141. Cai T, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Cavazos A, Han L, Kuruvilla V, Ma H, Weng C, Liu CG, Liu X, Konoplev S, Gu J, Tang G, Su X, Al-Atrash G, Ciurea S, Neelapu SS, Lane AA, Kantarjian H, Guzman ML, Pemmaraju N, Smith J, Thomas-Tikhonenko A, Konopleva M, Gouble A, Filipe S. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun. 2022 04 28; 13(1):2228. PMID: 35484100; PMCID: PMC9051102.
      Citations:    Fields:    Translation:HumansAnimalsCells
    142. Advani AS, DeAngelo DJ, Wang T, Neuhof A, Vandendries E, Kantarjian H, Jabbour E, Stelljes M. Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. Clin Lymphoma Myeloma Leuk. 2022 09; 22(9):e836-e843. PMID: 35643855.
      Citations:    Fields:    
    143. Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer. 2022 07 15; 128(14):2736-2745. PMID: 35452134; PMCID: PMC9232977.
      Citations:    Fields:    Translation:Humans
    144. Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022 07; 97(7):865-876. PMID: 35384048.
      Citations:    Fields:    Translation:Humans
    145. Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022 07; 97(7):856-864. PMID: 35357036.
      Citations: 1     Fields:    Translation:Humans
    146. Haddad F, Kantarjian H, Issa GC, Jabbour E, Sasaki K. Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma. 2022 07; 63(7):1714-1717. PMID: 35361036.
      Citations:    Fields:    Translation:Humans
    147. Gaballa MR, Banerjee P, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P, Milton DR. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022 03 24; 139(12):1908-1919. PMID: 34914826; PMCID: PMC8952188.
      Citations: 3     Fields:    Translation:Humans
    148. Januzzi JL, Garasic JM, Kasner SE, McDonald V, Petrie MC, Seltzer J, Mauro M, Croce K, Berman E, Deininger M, Pinilla-Ibarz J, Kim DW, DeAngelo DJ, Kantarjian H, Xu J, Hall T, Srivastava S, Naranjo D, Cortes J, Hochhaus A, Nicolini F. Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022 Mar 23; 15(1):33. PMID: 35317837; PMCID: PMC8941744.
      Citations:    Fields:    
    149. Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol. 2022 06 01; 97(6):E201-E204. PMID: 35266566.
      Citations:    Fields:    Translation:HumansCells
    150. Jammal N, Kantarjian HM, Haddad F, Jabbour EJ. Management of acute lymphoblastic leukemia in older adults. Clin Adv Hematol Oncol. 2022 Mar; 20(3):161-168. PMID: 36607346.
      Citations:    Fields:    
    151. Mukherjee A, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF, Milton DR. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893. PMID: 35225133; PMCID: PMC9730341.
      Citations:    Fields:    Translation:Humans
    152. Piya S, Yang Y, Bhattacharya S, Sharma P, Ma H, Mu H, He H, Ruvolo V, Baran N, Davis RE, Jain AK, Konopleava M, Kantarjian H, Andreeff M, You MJ, Borthakur G. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Leukemia. 2022 05; 36(5):1261-1273. PMID: 35173274; PMCID: PMC9061299.
      Citations:    Fields:    Translation:HumansAnimalsCells
    153. DiNardo CD, Garcia-Manero G, Kantarjian HM. Time to blur the blast boundaries. Cancer. 2022 04 15; 128(8):1568-1570. PMID: 35133004.
      Citations: 2     Fields:    Translation:Humans
    154. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 05; 36(5):1253-1260. PMID: 35132195.
      Citations:    Fields:    Translation:HumansCells
    155. Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022 01 29; 15(1):12. PMID: 35093134; PMCID: PMC8800349.
      Citations: 1     Fields:    Translation:Humans
    156. Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022 04 15; 128(8):1658-1665. PMID: 35077575.
      Citations:    Fields:    Translation:Humans
    157. Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022 01 25; 12(1):10. PMID: 35078972; PMCID: PMC8789767.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    158. Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022 03 01; 97(3):329-337. PMID: 34981570; PMCID: PMC8884919.
      Citations: 1     Fields:    Translation:Humans
    159. Januzzi JL, Garasic JM, Kasner SE, McDonald V, Petrie MC, Seltzer J, Mauro M, Croce K, Berman E, Deininger M, Pinilla-Ibarz J, Kim DW, DeAngelo DJ, Kantarjian H, Xu J, Hall T, Srivastava S, Naranjo D, Cortes J, Hochhaus A, Nicolini F. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022 01 06; 15(1):1. PMID: 34991679; PMCID: PMC8734305.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    160. Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K, Oran B. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 Jan; 36(1):298. PMID: 34876697.
      Citations:    Fields:    
    161. Short NJ, Kantarjian H, Dombret H, Ad?s L. The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. Cancer J. 2022 Jan-Feb 01; 28(1):29-36. PMID: 35072371.
      Citations:    Fields:    Translation:Humans
    162. Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel). 2021 Dec 29; 14(1). PMID: 35008312; PMCID: PMC8750927.
      Citations: 2     
    163. Ohanian M, Cancelas JA, Davenport R, Pullarkat V, Hervig T, Broome C, Marek K, Kelly M, Gul Z, Rugg N, Nestheide S, Kinne B, Szczepiorkowski Z, Kantarjian H, Pehta J, Biehl R, Yu A, Aung F, Antebi B, Fitzpatrick GM. Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies. Am J Hematol. 2022 03 01; 97(3):256-266. PMID: 34748664.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    164. Sasaki K, Kantarjian H, Jabbour E. Prediction for sustained deep molecular response for treatment-free remission. Leuk Lymphoma. 2022 01; 63(1):5-6. PMID: 34930078.
      Citations:    Fields:    Translation:Humans
    165. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations. Blood. 2021 12 16; 138(24):2589-2592. PMID: 34521099; PMCID: PMC8832441.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    166. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 12 14; 5(23):5415-5419. PMID: 34525185; PMCID: PMC9153023.
      Citations:    Fields:    Translation:Humans
    167. El Hussein S, Daver N, Liu JL, Kornblau S, Fang H, Konoplev S, Kantarjian H, Khoury JD. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2022 06; 22(6):e386-e391. PMID: 34980577.
      Citations:    Fields:    Translation:HumansCells
    168. Awada H, Durmaz A, Gurnari C, Kishtagari A, Meggendorfer M, Kerr CM, Kuzmanovic T, Durrani J, Shreve J, Nagata Y, Radivoyevitch T, Advani AS, Ravandi F, Carraway HE, Nazha A, Haferlach C, Saunthararajah Y, Scott J, Visconte V, Kantarjian H, Kadia T, Sekeres MA, Haferlach T, Maciejewski JP. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021 11 11; 138(19):1885-1895. PMID: 34075412; PMCID: PMC8767789.
      Citations: 2     Fields:    Translation:Humans
    169. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022 01 01; 97(1):68-78. PMID: 34716921.
      Citations:    Fields:    Translation:Humans
    170. Kantarjian HM, Wood BL, Horst HA, Zeng Y, Martinelli G, Zugmaier G, Br?ggemann M. Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers (Basel). 2021 Nov 09; 13(22). PMID: 34830762; PMCID: PMC8616108.
      Citations: 1     
    171. Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver N, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood. 2021 11 04; 138(18):1733-1739. PMID: 34115096; PMCID: PMC8569418.
      Citations: 1     Fields:    Translation:Humans
    172. Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, El Hussein S, Thompson P, Jain N, Kantarjian H, Jabbour E. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021 10 26; 5(20):3913-3918. PMID: 34464974; PMCID: PMC8945626.
      Citations:    Fields:    Translation:Humans
    173. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675. PMID: 34668451.
      Citations:    Fields:    Translation:Humans
    174. Kantarjian H, Short NJ, DiNardo C, Stein EM, Daver N, Perl AE, Wang ES, Wei A, Tallman M. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol. 2021 Dec; 8(12):e922-e933. PMID: 34687602; PMCID: PMC8996707.
      Citations: 2     Fields:    Translation:Humans
    175. DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, de Botton S, D?hner H. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021 11; 22(11):1597-1608. PMID: 34672961.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    176. Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver N, Pierce S, Jabbour E, Kadia T, DiNardo C, Garcia-Manero G, Qazilbash M, Konopleva M, Kantarjian H. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021 10 14; 138(15):1373-1377. PMID: 34098573.
      Citations: 2     Fields:    Translation:HumansCells
    177. Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ. The cure of leukemia through the optimist's prism. Cancer. 2022 01 15; 128(2):240-259. PMID: 34614211; PMCID: PMC8738114.
      Citations:    Fields:    Translation:Humans
    178. George B, Kantarjian H, Baran N, Krocker JD, Rios A. TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation. Int J Mol Sci. 2021 Oct 05; 22(19). PMID: 34639121; PMCID: PMC8509740.
      Citations: 3     Fields:    Translation:Humans
    179. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021 09 29; 11(9):162. PMID: 34588432; PMCID: PMC8481264.
      Citations: 2     Fields:    Translation:Humans
    180. Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma. 2021 12; 62(14):3501-3505. PMID: 34474640; PMCID: PMC10423012.
      Citations:    Fields:    Translation:Humans
    181. Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger SM, Butrym A, Gaidano G, Thomas XG, Montesinos P, Rizzieri DA, Quick DP, Venugopal P, Gaur R, Maness LJ, Kadia TM, Ravandi F, Buyse ME, Chiao JH. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 12 01; 127(23):4421-4431. PMID: 34424530; PMCID: PMC9523989.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    182. Short NJ, Kantarjian H, Jabbour E. SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2022 02; 22(2):61-66. PMID: 34561201.
      Citations:    Fields:    Translation:HumansCells
    183. Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 11 01; 96(11):1420-1428. PMID: 34351647; PMCID: PMC9167467.
      Citations: 2     Fields:    Translation:Humans
    184. Short NJ, Kantarjian H. When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era. J Clin Oncol. 2021 10 01; 39(28):3104-3108. PMID: 34406793; PMCID: PMC8478366.
      Citations: 3     Fields:    Translation:Humans
    185. Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021 12; 62(14):3402-3410. PMID: 34380367; PMCID: PMC8939853.
      Citations: 1     Fields:    Translation:Humans
    186. Abou Dalle I, Kantarjian H, Daver N, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol. 2021 Dec; 100(12):2957-2960. PMID: 34350483.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    187. Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer. 2021 11 15; 127(22):4213-4220. PMID: 34343352; PMCID: PMC8556232.
      Citations: 4     Fields:    Translation:Humans
    188. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387. PMID: 34340254.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    189. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561. PMID: 34329576; PMCID: PMC8884174.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    190. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219. PMID: 34110383; PMCID: PMC8193546.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    191. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130. PMID: 33853292; PMCID: PMC8327731.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    192. Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021 10 15; 127(20):3772-3781. PMID: 34255353; PMCID: PMC10462434.
      Citations: 12     Fields:    Translation:Humans
    193. Jabbour E, Patel K, Jain N, Duose D, Luthra R, Short NJ, Zugmaier G, San Lucas A, Velasco K, Tran Q, Zaman F, Konopleva M, Kantarjian H. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. Am J Hematol. 2021 10 01; 96(10):E379-E383. PMID: 34161631.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    194. Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, Boquimpani C, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Cacciatore S, Titorenko K, Aimone P, Saglio G, le Coutre P, Etienne G, Pasquini R, Zanichelli M, Bendit I, Hochhaus A. Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 Jul; 35(7):2142-2143. PMID: 34108614; PMCID: PMC8414785.
      Citations: 2     Fields:    
    195. Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021 06 30; 11(6):123. PMID: 34193815; PMCID: PMC8245494.
      Citations: 5     Fields:    Translation:Humans
    196. Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021 10 01; 127(19):3541-3551. PMID: 34182597.
      Citations: 4     Fields:    Translation:Humans
    197. Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021 11; 35(11):3044-3058. PMID: 34172894.
      Citations: 4     Fields:    Translation:Humans
    198. Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021 10 01; 127(19):3552-3565. PMID: 34161603; PMCID: PMC10015977.
      Citations: 3     Fields:    Translation:Humans
    199. Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol. 2021 10 10; 39(29):3261-3272. PMID: 34156898; PMCID: PMC8500663.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    200. Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389. PMID: 34138471.
      Citations: 1     Fields:    Translation:HumansCells
    201. Borthakur G, Kantarjian H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021 06 16; 11(6):114. PMID: 34135311; PMCID: PMC8209225.
      Citations: 7     Fields:    Translation:HumansCells
    202. Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K, Oran B. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 01; 36(1):257-262. PMID: 34135465.
      Citations: 3     Fields:    Translation:Humans
    203. Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021 06 15; 14(1):94. PMID: 34130720; PMCID: PMC8204504.
      Citations: 3     Fields:    Translation:Humans
    204. Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021 09; 35(9):2482-2495. PMID: 34131281.
      Citations: 13     Fields:    Translation:Humans
    205. Kim K, Jabbour E, Short NJ, Kebriaei P, Kantarjian H, Ravandi F. Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant. Curr Oncol Rep. 2021 06 14; 23(8):95. PMID: 34125415.
      Citations:    Fields:    Translation:HumansCells
    206. Wei AH, Roboz GJ, Kantarjian HM. Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2742-2748. PMID: 34086506.
      Citations:    Fields:    Translation:Humans
    207. Kantarjian HM, Short NJ, Fathi AT, Marcucci G, Ravandi F, Tallman M, Wang ES, Wei AH. Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. Clin Lymphoma Myeloma Leuk. 2021 09; 21(9):580-597. PMID: 34176779.
      Citations: 6     Fields:    Translation:Humans
    208. Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):1000-1007. PMID: 33991360; PMCID: PMC9096877.
      Citations: 2     Fields:    Translation:HumansCells
    209. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778. PMID: 34043428; PMCID: PMC8407653.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    210. Short NJ, Tallman MS, Pollyea DA, Ravandi F, Kantarjian H. Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. J Clin Oncol. 2021 08 10; 39(23):2535-2538. PMID: 34043455.
      Citations: 5     Fields:    Translation:Humans
    211. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924. PMID: 33901324.
      Citations: 4     Fields:    Translation:Humans
    212. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429. PMID: 34007049.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    213. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021 05 18; 72(10):1755-1763. PMID: 32236406; PMCID: PMC8130026.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    214. Kantarjian H. Emil J. Freireich: Legend in cancer research (March 16, 1927-February 1, 2021). Bone Marrow Transplant. 2021 07; 56(7):1764-1767. PMID: 33981012.
      Citations:    Fields:    
    215. Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Loscocco F, Visani G, Martinelli G, Kantarjian H, Romano A, Curti A. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol. 2021; 11:656218. PMID: 34041025; PMCID: PMC8143531.
      Citations: 18     
    216. Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607. PMID: 33972549; PMCID: PMC8110775.
      Citations: 12     Fields:    Translation:HumansCells
    217. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2021 May 10; 12(1):2823. PMID: 33972555; PMCID: PMC8110810.
      Citations: 1     Fields:    
    218. Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol. 2021 08 01; 96(8):E275-E279. PMID: 33891709; PMCID: PMC9154045.
      Citations:    Fields:    Translation:Humans
    219. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124. PMID: 33914911.
      Citations:    Fields:    Translation:Humans
    220. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021 04 27; 5(8):2173-2183. PMID: 33885753; PMCID: PMC8095152.
      Citations: 4     Fields:    Translation:Humans
    221. Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249. PMID: 33811786.
      Citations: 1     Fields:    Translation:HumansCells
    222. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883. PMID: 33792630; PMCID: PMC8045494.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    223. Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021 07 01; 96(7):E229-E232. PMID: 33780038; PMCID: PMC9278812.
      Citations: 4     Fields:    Translation:HumansCells
    224. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 05; 35(5):1494-1499. PMID: 33846541.
      Citations: 2     Fields:    Translation:Humans
    225. Kantarjian HM. Remembering Emil J Freireich: Trailblazing pioneer and giant in cancer research. Am J Hematol. 2021 06 01; 96(6):647-649. PMID: 33735488.
      Citations:    Fields:    
    226. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 08 01; 127(15):2641-2647. PMID: 33823073.
      Citations: 4     Fields:    Translation:HumansCells
    227. Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021 06 15; 127(12):2049-2061. PMID: 33818756.
      Citations: 8     Fields:    Translation:Humans
    228. Sasaki K, Jabbour E, Short NJ, Jain N, Ravandi F, Pui CH, Kantarjian H. Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol. 2021 06 01; 96(6):650-658. PMID: 33709456; PMCID: PMC9517941.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    229. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656. PMID: 33793964.
      Citations: 3     Fields:    Translation:HumansCells
    230. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021 07 15; 127(14):2489-2499. PMID: 33793970; PMCID: PMC8249340.
      Citations: 4     Fields:    Translation:Humans
    231. Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Pollyea DA, McCloskey JK, Odenike O, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS, D?hner H, L?wenberg B. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803. PMID: 33024987; PMCID: PMC8020270.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    232. Zeng Z, Ly C, Daver N, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. Ann Hematol. 2021 Jun; 100(6):1485-1496. PMID: 33787984.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    233. Kantarjian HM. Honoring Emil J. Freireich: A Visionary Medical Cancer Researcher-March 21, 1927-February 1, 2021. Blood Cancer Discov. 2021 May; 2(3):190-191. PMID: 35015670; PMCID: PMC8514001.
      Citations:    Fields:    
    234. Cerchione C, Daver N, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G, Kantarjian H, Romano A. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Front Oncol. 2021; 11:639387. PMID: 33898313; PMCID: PMC8063727.
      Citations: 7     
    235. Jabbour E, Kantarjian H. A new era in the treatment of acute lymphoblastic leukemia. Blood. 2021 03 25; 137(12):1563-1564. PMID: 33764428; PMCID: PMC9999037.
      Citations: 1     Fields:    Translation:Humans
    236. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749. PMID: 33767403.
      Citations:    Fields:    Translation:Humans
    237. Jabbour E, Paul S, Kantarjian H. The clinical development of antibody-drug conjugates - lessons from leukaemia. Nat Rev Clin Oncol. 2021 07; 18(7):418-433. PMID: 33758376.
      Citations: 6     Fields:    Translation:HumansAnimals
    238. Cortes JE, Kantarjian HM, Mauro MJ, An F, Nick S, Leip E, Gambacorti-Passerini C, Br?mmendorf TH. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol. 2021 Jun; 106(6):808-820. PMID: 33638218.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    239. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038. PMID: 33740268.
      Citations: 1     Fields:    Translation:HumansCells
    240. Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021 04 15; 127(8):1186-1207. PMID: 33734442.
      Citations: 18     Fields:    Translation:Humans
    241. Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 05 01; 96(5):589-598. PMID: 33639000.
      Citations: 7     Fields:    Translation:Humans
    242. Stein AS, Martinelli G, Kantarjian H, Chen Y, Zugmaier G, Topp MS, G?kbuget N, Horst HA, Boissel N, Br?ggemann M. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. Cancer Med. 2021 04; 10(8):2601-2610. PMID: 33734596; PMCID: PMC8026950.
      Citations: 1     Fields:    Translation:Humans
    243. Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J. 2021 03 17; 11(3):60. PMID: 33731681; PMCID: PMC7969746.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    244. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52. PMID: 33677472; PMCID: PMC7936977.
      Citations: 2     Fields:    Translation:Humans
    245. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898. PMID: 32499238; PMCID: PMC7927994.
      Citations: 13     Fields:    Translation:Humans
    246. Kantarjian HM. Emil J. Freireich 1927-2021. Nat Cancer. 2021 03; 2(3):251-252. PMID: 35121959.
      Citations:    
    247. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34. PMID: 33618754; PMCID: PMC7901199.
      Citations:    Fields:    
    248. Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021 02 22; 11(2):41. PMID: 33619261; PMCID: PMC7900255.
      Citations: 45     Fields:    Translation:HumansAnimals
    249. Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063. PMID: 33618432; PMCID: PMC8944196.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    250. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E154-E157. PMID: 33580980; PMCID: PMC8237705.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    251. Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O'Brien SM, Wang T, Paccagnella ML, Nguyen K, Sleight B, Vandendries E, Neuhof A, Laird AD, Advani AS, Stelljes M. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754. PMID: 33602684.
      Citations: 3     Fields:    Translation:Humans
    252. Wei AH, Ribera JM, Larson RA, Ritchie D, Ghobadi A, Chen Y, Anderson A, Dos Santos CE, Franklin J, Kantarjian H. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021 08; 35(8):2220-2231. PMID: 33542479; PMCID: PMC8324476.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    253. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 02 01; 11(2):25. PMID: 33563904; PMCID: PMC7873265.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    254. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213. PMID: 33585199; PMCID: PMC7878971.
      Citations: 5     
    255. Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol. 2020; 11:590494. PMID: 33552049; PMCID: PMC7859512.
      Citations: 4     Fields:    Translation:HumansCells
    256. Montalban-Bravo G, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, Class CA, Sasaki K, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien KS, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leuk Res. 2021 02; 101:106511. PMID: 33517186.
      Citations: 3     Fields:    Translation:HumansCells
    257. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900. PMID: 33449377.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    258. Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, List AF, Komrokji RS, Fenaux P. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021 05 10; 39(14):1584-1594. PMID: 33449813; PMCID: PMC8099410.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    259. Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, Boquimpani C, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Cacciatore S, Titorenko K, Aimone P, Saglio G, le Coutre P, Etienne G, Pasquini R, Zanichelli M, Bendit I, Hochhaus A. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 02; 35(2):440-453. PMID: 33414482; PMCID: PMC7862065.
      Citations: 24     Fields:    Translation:Humans
    260. Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):318-327.e6. PMID: 33551345; PMCID: PMC8849582.
      Citations: 3     Fields:    Translation:Humans
    261. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291. PMID: 33264443; PMCID: PMC8128145.
      Citations: 15     Fields:    Translation:Humans
    262. Koller PB, Zhang H, Kantarjian H, Jabbour E, Pierce S, Gocho Y, Roberts KG, Yang W, Mullighan CG, Yang J, Konopleva M, Jain N. GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis. Am J Hematol. 2021 03 01; 96(3):E71-E74. PMID: 33275800.
      Citations: 2     Fields:    Translation:Humans
    263. Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020 12 22; 4(24):6117-6126. PMID: 33351107; PMCID: PMC7757010.
      Citations: 12     Fields:    Translation:Humans
    264. Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Maus MV, Frigault MJ, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W, UCART19 Group, Boissel N, Baruchel A. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020 12 12; 396(10266):1885-1894. PMID: 33308471.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    265. Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma. 2021 04; 62(4):909-917. PMID: 33283580.
      Citations: 1     Fields:    Translation:Humans
    266. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134. PMID: 33681815; PMCID: PMC7935111.
      Citations: 9     Fields:    Translation:Humans
    267. Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020 Dec 01; 6(12):1890-1899. PMID: 33030517; PMCID: PMC7545346.
      Citations: 30     Fields:    Translation:Humans
    268. Samra B, Kantarjian HM, Sasaki K, Alotaibi AS, Konopleva M, O'Brien S, Ferrajoli A, Garris R, Nunez CA, Kadia TM, Short NJ, Jabbour E. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Acta Haematol. 2021; 144(3):285-292. PMID: 33238261.
      Citations:    Fields:    Translation:HumansCells
    269. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020 11 24; 4(22):5681-5689. PMID: 33211826; PMCID: PMC7686900.
      Citations: 11     Fields:    Translation:Humans
    270. Stock W, Martinelli G, DeAngelo DJ, Advani AS, O'Brien S, Liedtke M, Merchant AA, Cassaday RD, Wang T, Zhang H, Vandendries E, Jabbour E, Marks DI, Kantarjian HM, Stelljes M, G?kbuget N. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 03 15; 127(6):905-913. PMID: 33231879; PMCID: PMC7983935.
      Citations: 8     Fields:    Translation:HumansCells
    271. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53. PMID: 33156969.
      Citations: 3     Fields:    Translation:Humans
    272. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 Nov 19; 11(1):5996. PMID: 33214561; PMCID: PMC7677309.
      Citations: 3     Fields:    
    273. Chew S, Jammal N, Kantarjian H, Jabbour E. Monoclonal antibodies in frontline acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2020 12; 33(4):101226. PMID: 33279178.
      Citations: 1     Fields:    Translation:Humans
    274. Jammal N, Chew S, Jabbour E, Kantarjian H. Antibody based therapy in relapsed acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2020 12; 33(4):101225. PMID: 33279181.
      Citations: 1     Fields:    Translation:Humans
    275. Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv. 2020 11 10; 4(21):5336-5342. PMID: 33112940; PMCID: PMC7656917.
      Citations: 9     Fields:    Translation:Humans
    276. Zugmaier G, Stein AS, Chen Y, Ribera JM, Horst HA, Kantarjian HM, Topp MS, G?kbuget N, Dombret H, Bargou RC. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Cancer. 2021 02 15; 127(4):554-559. PMID: 33141929; PMCID: PMC7894150.
      Citations: 3     Fields:    Translation:HumansCells
    277. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 02 01; 127(3):381-390. PMID: 33119202.
      Citations: 1     Fields:    Translation:HumansCells
    278. DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Martinelli G, Patel PA, Tan P, Zeidan AM, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P, D?hner H, Raffoux E, de Botton S. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2021 01 01; 39(1):57-65. PMID: 33119479; PMCID: PMC7771719.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    279. Jabbour E, Kantarjian H. The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 01; 21(1):63-65. PMID: 33191168.
      Citations:    Fields:    Translation:Humans
    280. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327. PMID: 33087716; PMCID: PMC7577981.
      Citations: 66     Fields:    Translation:HumansAnimals
    281. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132. PMID: 33032648; PMCID: PMC7542942.
      Citations: 7     Fields:    Translation:Humans
    282. Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789. PMID: 32492706; PMCID: PMC8209550.
      Citations: 3     Fields:    Translation:Humans
    283. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol. 2020 12; 95(12):E326-E329. PMID: 32886803.
      Citations:    Fields:    Translation:HumansCells
    284. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228. PMID: 32955970.
      Citations:    Fields:    Translation:HumansCells
    285. Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. Int J Hematol. 2021 Jan; 113(1):92-99. PMID: 32951163.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    286. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736. PMID: 32896301; PMCID: PMC7549397.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    287. Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. 2020 11; 95(11):E313-E315. PMID: 32804409.
      Citations:    Fields:    Translation:Humans
    288. Jabbour E, Kantarjian H. Management of Older Patients with Acute Lymphocytic Leukemia - Novel Treatment Strategies. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S30-S31. PMID: 32862859.
      Citations: 1     Fields:    Translation:Humans
    289. Lonial S, Kantarjian H, Freireich EJ. Message from the Chairmen. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S1. PMID: 32862847.
      Citations:    Fields:    Translation:Humans
    290. DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2021 05; 16(5):567-576. PMID: 32856987; PMCID: PMC8078744.
      Citations: 3     Fields:    Translation:HumansCells
    291. Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020 11; 95(11):1296-1303. PMID: 32697348.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    292. Chen J, Haughey M, Vandendries E, DeAngelo DJ, Kantarjian HM, Ruiz-Garcia A. Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Transl Sci. 2021 01; 14(1):184-193. PMID: 32812370; PMCID: PMC7877846.
      Citations: 1     Fields:    Translation:Humans
    293. Cassaday RD, Marks DI, DeAngelo DJ, Jabbour EJ, Advani AS, O'Brien S, Wang T, Neuhof A, Vandendries E, Kantarjian HM, Stock W, Stelljes M. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81. PMID: 32805058.
      Citations:    Fields:    Translation:Humans
    294. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295. PMID: 32681739.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    295. DeAngelo DJ, Advani AS, Marks DI, Liedtke M, Stock W, Jabbour E, Merchant A, Wang T, Vandendries E, Neuhof A, Kantarjian H, O'Brien S, Stelljes M, G?kbuget N. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020 08 07; 10(8):81. PMID: 32769965; PMCID: PMC7414105.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    296. Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR, Busque L. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 08 06; 136(6):674-683. PMID: 32285126; PMCID: PMC7414597.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    297. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020 12; 61(13):3120-3127. PMID: 32755333.
      Citations: 2     Fields:    Translation:Humans
    298. Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, Jain N, Konopleva M, Kantarjian H, Jabbour E. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020 09; 95(9):E245-E247. PMID: 32501545.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    299. Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020 Oct; 95(10):1127-1134. PMID: 32557828.
      Citations: 1     Fields:    
    300. Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020 10 01; 126(19):4322-4331. PMID: 32697338; PMCID: PMC7875207.
      Citations: 4     Fields:    Translation:Humans
    301. Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma. 2020 12; 61(12):2811-2820. PMID: 32662346; PMCID: PMC8424781.
      Citations: 1     Fields:    Translation:Humans
    302. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533. PMID: 32589978.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    303. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700. PMID: 32561839.
      Citations: 6     Fields:    Translation:Humans
    304. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924. PMID: 32546726.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    305. Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):e871-e882. PMID: 32792304.
      Citations: 4     Fields:    Translation:Humans
    306. Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020 06 05; 13(1):70. PMID: 32503572; PMCID: PMC7275444.
      Citations: 27     Fields:    Translation:HumansCells
    307. Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020 05 26; 10(5):61. PMID: 32457305; PMCID: PMC7250857.
      Citations: 3     Fields:    Translation:HumansCells
    308. Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. 2020 09; 95(9):E225-E228. PMID: 32356320.
      Citations: 3     Fields:    Translation:Humans
    309. Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM, Einsele H. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020 07 15; 126(14):3192-3201. PMID: 32401342.
      Citations: 40     Fields:    Translation:HumansCells
    310. Choe S, Wang H, DiNardo CD, Stein EM, Roboz GJ, Altman JK, Mims AS, Watts JM, Pollyea DA, Fathi AT, Tallman MS, Kantarjian HM, Stone RM, Quek L, Konteatis Z, Dang L, Nicolay B, Nejad P, Liu G, Zhang V, Liu H, Goldwasser M, Liu W, Marks K, Bowden C, Biller SA, Attar EC, Wu B, de Botton S. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020 05 12; 4(9):1894-1905. PMID: 32380538; PMCID: PMC7218420.
      Citations: 53     Fields:    Translation:Humans
    311. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol. 2021; 144(2):132-145. PMID: 32392559; PMCID: PMC7270066.
      Citations: 18     Fields:    Translation:HumansCellsPHPublic Health
    312. Jabbour E, Advani AS, DeAngelo DJ, Marks DI, Stock W, O'Brien S, Cassaday RD, Wang T, Neuhof A, Vandendries E, Kantarjian H, Stelljes M, G?kbuget N. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leuk Lymphoma. 2020 08; 61(8):2012-2015. PMID: 32378440.
      Citations: 1     Fields:    Translation:Humans
    313. Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020 05 04; 10(5):47. PMID: 32366832; PMCID: PMC7198507.
      Citations: 2     Fields:    Translation:Humans
    314. Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J. 2020 05 04; 10(5):48. PMID: 32366841; PMCID: PMC7198530.
      Citations: 2     Fields:    Translation:Humans
    315. Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677. PMID: 32324887; PMCID: PMC7189293.
      Citations: 9     Fields:    Translation:Humans
    316. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1690-1699. PMID: 32330243; PMCID: PMC7189295.
      Citations: 1     Fields:    Translation:Humans
    317. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739. PMID: 32170867.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    318. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol. 2020; 143(6):567-573. PMID: 32289808; PMCID: PMC7839068.
      Citations: 18     Fields:    Translation:Humans
    319. Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020 04 14; 4(7):1311-1320. PMID: 32251497; PMCID: PMC7160266.
      Citations: 38     Fields:    Translation:Humans
    320. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020 06; 95(6):691-709. PMID: 32239758.
      Citations: 54     Fields:    Translation:HumansCells
    321. Garcia-Manero G, Pemmaraju N, Alvarado Y, Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A, Mukherjee S, Gerds A, Carraway HE, Nazha A, Iwamura H, Murase M, Bavisotto L, Kurman M, Maier G, Johansen M, Sekeres MA. Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Lymphoma. 2020 08; 61(8):1943-1953. PMID: 32264726.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    322. Bazarbachi A, Bug G, Ciceri F, Dalle IA, Floisand Y, Giebel S, Gilleece M, Gorin NC, Jabbour E, Aljurf M, Kantarjian H, Kharfan-Dabaja M, Labopin M, Lanza F, Peric Z, Prebet T, Ravandi F, Schmid C, Shouval R, Spyridonidis A, Versluis J, Vey N, Savani BN, Nagler A, Baron F, Brissot E, D?hner H, Esteve J, Malard F, Ruggeri A, Sanz J, Mohty M. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020 06; 105(6):1507-1516. PMID: 32241850; PMCID: PMC7271578.
      Citations: 27     Fields:    Translation:Humans
    323. Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R, Quesada AE. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 09; 33(9):1678-1689. PMID: 32238878.
      Citations: 2     Fields:    Translation:HumansCells
    324. Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e597-e605. PMID: 32303488.
      Citations: 1     Fields:    Translation:HumansCells
    325. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622. PMID: 32112433.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    326. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020 03 12; 135(11):791-803. PMID: 31932844; PMCID: PMC7068032.
      Citations: 113     Fields:    Translation:Humans
    327. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865. PMID: 31961918; PMCID: PMC8212349.
      Citations: 8     Fields:    Translation:HumansCells
    328. Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, Tallman MS, Kantarjian HM, de Botton S. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020 Apr; 7(4):e309-e319. PMID: 32145771.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    329. Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N, Oran B. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2193-2205. PMID: 32125707.
      Citations: 12     Fields:    Translation:Humans
    330. Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Larson RA, Lipton JH, Mayer J, Pane F, Radich JP, Richter J, Rosti G, Rousselot P, Saglio G, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hochhaus A, Kim DW, Mahon FX, Nicolini F, Niederwieser D, Rea D, Sau?ele S, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 04; 34(4):966-984. PMID: 32127639; PMCID: PMC7214240.
      Citations: 204     Fields:    Translation:Humans
    331. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492. PMID: 32099037.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    332. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513. PMID: 31895947; PMCID: PMC7019190.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    333. Roboz GJ, DiNardo CD, Stein EM, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM, de Botton S. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 02 13; 135(7):463-471. PMID: 31841594; PMCID: PMC7019193.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    334. Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020 02 11; 4(3):449-457. PMID: 32012214; PMCID: PMC7013258.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    335. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020 02 11; 4(3):482-495. PMID: 32027746; PMCID: PMC7013259.
      Citations: 20     Fields:    Translation:Humans
    336. Chien KS, Class CA, Montalban-Bravo G, Wei Y, Sasaki K, Naqvi K, Ganan-Gomez I, Yang H, Soltysiak KA, Kanagal-Shamanna R, Do KA, Kantarjian HM, Garcia-Manero G. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma. 2020 06; 61(6):1493-1499. PMID: 32036728; PMCID: PMC7836710.
      Citations: 3     Fields:    Translation:HumansCells
    337. Kurzrock R, Kantarjian HM, Kesselheim AS, Sigal EV. New drug approvals in oncology. Nat Rev Clin Oncol. 2020 03; 17(3):140-146. PMID: 32020042.
      Citations: 7     Fields:    Translation:Humans
    338. Xie W, Tang G, Wang E, Kim Y, Cloe A, Shen Q, Zhou Y, Garcia-Manero G, Loghavi S, Hu AY, Wang S, Bueso-Ramos CE, Kantarjian HM, Medeiros LJ, Hu S. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? Ann Hematol. 2020 Mar; 99(3):487-500. PMID: 32006151.
      Citations:    Fields:    Translation:HumansCells
    339. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM, Nogueras-Gonz?lez GM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511. PMID: 31999839.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    340. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459. PMID: 31999850.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    341. Rausch CR, Jabbour EJ, Kantarjian HM, Kadia TM. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer. 2020 03 15; 126(6):1152-1160. PMID: 31794095.
      Citations: 6     Fields:    Translation:Humans
    342. Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ. Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019 Dec; 17(12):686-696. PMID: 31851157.
      Citations: 2     Fields:    Translation:Humans
    343. Jabbour E, Advani A, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H, G?kbuget N, Stelljes M. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283. PMID: 31790983.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    344. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150. PMID: 31682008.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    345. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer. 2020 02 15; 126(4):765-774. PMID: 31742675.
      Citations: 16     Fields:    Translation:Humans
    346. Montalban-Bravo G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, Sasaki K, Richard-Carpentier G, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien K, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia. 2020 03; 34(3):872-881. PMID: 31719677; PMCID: PMC7056563.
      Citations: 5     Fields:    Translation:HumansCells
    347. Kantarjian HM, Stein AS, Fielding AK, Heffner L, Litzow M, O'Brien S, Zugmaier G, Gao S, Nagorsen D, Forman SJ, G?kbuget N, Br?ggemann M, Bargou RC, Dombret H, Rigal-Huguet F, Topp MS. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2019 10 22; 3(20):3033-3037. PMID: 31648325; PMCID: PMC6849936.
      Citations: 4     Fields:    Translation:Humans
    348. Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019 12; 94(12):1388-1395. PMID: 31595534.
      Citations: 7     Fields:    Translation:HumansCells
    349. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019 12; 94(12):1382-1387. PMID: 31595538.
      Citations: 5     Fields:    Translation:Humans
    350. Getta B, Masarova L, Famulare C, Schulman J, Arcila ME, Kantarjian HM, Levine RL, Rampal RK, Verstovsek S, Santos FPS, Datoguia TS, Puga RD, Alves Paiva RM, Hamerschlak N, Campregher PV. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia. 2020 03; 34(3):799-810. PMID: 31628430; PMCID: PMC7158221.
      Citations: 16     Fields:    Translation:Humans
    351. Rambaldi A, Ribera JM, Kantarjian HM, Ottmann OG, Stein AS, Tuglus CA, Zhao X, Kim C, Martinelli G, Dombret H. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Cancer. 2020 01 15; 126(2):304-310. PMID: 31626339; PMCID: PMC7003760.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    352. Rafei H, Kantarjian HM, Jabbour EJ. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. Br J Haematol. 2020 01; 188(2):207-223. PMID: 31566728.
      Citations: 6     Fields:    Translation:HumansCells
    353. Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):212-218. PMID: 32035785.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    354. Fares J, Khalil M, Chaftari AM, Hachem R, Jiang Y, Kantarjian HM, Raad II. Impact of Catheter Management on Clinical Outcome in Adult Cancer Patients With Gram-Negative Bacteremia. Open Forum Infect Dis. 2019 Oct; 6(10):ofz357. PMID: 31660336; PMCID: PMC6765346.
      Citations: 4     
    355. Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, Garcia-Manero G, Borthakur G, Naqvi K, Meyer M, Pudipeddi M, Nidarmarthy S, Vaddi K, Kantarjian H. Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica. 2020 06; 105(6):1567-1574. PMID: 31558670; PMCID: PMC7271599.
      Citations: 10     Fields:    Translation:Humans
    356. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75. PMID: 31553487; PMCID: PMC8529949.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    357. Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020 02; 61(2):288-297. PMID: 31547736.
      Citations: 18     Fields:    Translation:Humans
    358. Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019 11; 8(15):6559-6565. PMID: 31502383; PMCID: PMC6825993.
      Citations: 5     Fields:    Translation:Humans
    359. Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020 02; 95(2):227-229. PMID: 31400013.
      Citations: 8     Fields:    Translation:Humans
    360. Jones G, Kantarjian H. The many roads to universal health care in the USA. Lancet Oncol. 2019 10; 20(10):e601-e605. PMID: 31473128.
      Citations: 4     Fields:    Translation:Humans
    361. Marks DI, van Oostrum I, Mueller S, Welch V, Vandendries E, Loberiza FR, Su Y, Kantarjian HM, B?hme S, Stelljes M. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment. Cancer Med. 2019 10; 8(13):5959-5968. PMID: 31436395; PMCID: PMC6792500.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    362. Jabbour EJ, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS, G?kbuget N. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019 Dec 01; 125(23):4181-4192. PMID: 31433496.
      Citations: 12     Fields:    Translation:Humans
    363. Botella C, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Recher C, Bertoli S, Micol JB, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Thiede C, Serve H, Ehninger G, Kramer M, Krug U, Angenendt L, R?llig C, Montesinos P, Mart?nez-Cuadr?n D, Barragan E, Garc?a R, Mart?nez P, H?glund M, Lehmann S, Pigneux A, Dumas PY, Dombret H, Preudhomme C, Terr? C, R?cil Z, Nov?k J, ??k P, Exeler R, Wagenf?hr L, St?lzel F, Stelljes M, Lenz G, Mikesch JH, Berdel WE, Schliemann C. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. J Clin Oncol. 2019 10 10; 37(29):2632-2642. PMID: 31430225; PMCID: PMC8462529.
      Citations: 15     Fields:    Translation:Humans
    364. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488. PMID: 31400961; PMCID: PMC6778960.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    365. Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. Am J Hematol. 2019 10; 94(10):E256-E259. PMID: 31273842.
      Citations:    Fields:    Translation:HumansCells
    366. Chung W, Kelly AD, Kropf P, Fung H, Jelinek J, Su XY, Roboz GJ, Kantarjian HM, Azab M, Issa JJ. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clin Epigenetics. 2019 07 22; 11(1):106. PMID: 31331399; PMCID: PMC6647096.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    367. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Nov 01; 125(21):3755-3766. PMID: 31310323.
      Citations: 10     Fields:    Translation:HumansCells
    368. Sasaki K, Kantarjian HM, Jabbour EJ. Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? Cancer. 2019 11 01; 125(21):3891-3892. PMID: 31291004.
      Citations:    Fields:    Translation:Humans
    369. Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):471-479. PMID: 31307896.
      Citations:    Fields:    Translation:Humans
    370. Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma. 2019 12; 60(13):3292-3295. PMID: 31246142.
      Citations: 2     Fields:    Translation:Humans
    371. Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Konopleva M, Andreeff M, Cortes J, Ravandi F, Nogueras Gonz?lez GM. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019 09; 94(9):984-991. PMID: 31237017.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    372. Shih YT, Cortes JE, Kantarjian HM. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019 Aug; 6(8):e398-e408. PMID: 31208943; PMCID: PMC6658341.
      Citations: 14     Fields:    Translation:Humans
    373. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019 09 15; 125(18):3219-3224. PMID: 31150121.
      Citations: 5     Fields:    Translation:Humans
    374. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103. PMID: 31141631.
      Citations: 139     Fields:    Translation:HumansCTClinical Trials
    375. Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma. 2019 12; 60(13):3172-3180. PMID: 31125272.
      Citations:    Fields:    Translation:Humans
    376. Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020 03; 105(3):697-707. PMID: 31123034; PMCID: PMC7049339.
      Citations: 30     Fields:    Translation:HumansCells
    377. Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548. PMID: 31115909.
      Citations: 9     Fields:    Translation:HumansCells
    378. Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Ther Adv Hematol. 2019; 10:2040620719849496. PMID: 31205644; PMCID: PMC6535741.
      Citations: 7     
    379. Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2019 11; 60(11):2606-2621. PMID: 31092071.
      Citations: 20     Fields:    Translation:HumansAnimals
    380. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539. PMID: 31076409; PMCID: PMC6517659.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    381. Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP, Quesada AE. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766. PMID: 30963592.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    382. Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327. PMID: 31060979; PMCID: PMC9012213.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    383. Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell. 2019 05 13; 35(5):721-737.e9. PMID: 31056398; PMCID: PMC6620028.
      Citations: 79     Fields:    Translation:HumansAnimalsCells
    384. Kantarjian HM. Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019 May; 17(5):268-270. PMID: 31188803.
      Citations:    Fields:    Translation:Humans
    385. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol. 2019 07; 94(7):E188-E190. PMID: 30977182; PMCID: PMC6566858.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    386. Marks DI, Kebriaei P, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, Zhang H, Loberiza F, Vandendries E, DeAngelo DJ, Stelljes M, G?kbuget N. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2019 09; 25(9):1720-1729. PMID: 31039409.
      Citations: 11     Fields:    Translation:Humans
    387. Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 04 25; 380(17):1628-1637. PMID: 31018069.
      Citations: 83     Fields:    Translation:HumansCellsCTClinical Trials
    388. Stein AS, Kantarjian H, Litzow MR, Rambaldi A, Ribera JM, Zhang A, Zimmerman Z, Zugmaier G, G?kbuget N, Bargou R, Topp MS. Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 08; 25(8):1498-1504. PMID: 31002989.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    389. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019 08 01; 125(15):2579-2586. PMID: 30985931; PMCID: PMC6625850.
      Citations: 20     Fields:    Translation:Humans
    390. Pollyea DA, Tallman MS, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM, de Botton S. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019 11; 33(11):2575-2584. PMID: 30967620; PMCID: PMC9724489.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    391. Schuh AC, Wei AH, Durrant S, Bacon CL, Tran Q, Zimmerman Z, Kantarjian H, Dombret H, Topp MS. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019 09; 60(9):2214-2222. PMID: 30947585.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    392. Richard-Carpentier G, Kantarjian H, Jabbour E. Recent Advances in Adult Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2019 04; 14(2):106-118. PMID: 30879177.
      Citations: 12     Fields:    Translation:Humans
    393. Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019 Apr; 6(4):e194-e203. PMID: 30926081.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    394. Kantarjian HM, DeAngelo DJ, Liedtke M, Stock W, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS, Stelljes M, G?kbuget N. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487. PMID: 30920645; PMCID: PMC6618133.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    395. Jain P, Kantarjian H, Boddu PC, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE, Nogueras-Gonz?lez GM. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861. PMID: 30885996; PMCID: PMC6436011.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    396. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 03 26; 3(6):922-933. PMID: 30902805; PMCID: PMC6436014.
      Citations: 21     Fields:    Translation:Humans
    397. Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol. 2019 06; 94(6):E158-E160. PMID: 30838674; PMCID: PMC6602057.
      Citations: 6     Fields:    Translation:Humans
    398. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. 2019 07 01; 125(13):2233-2241. PMID: 30861111; PMCID: PMC6742577.
      Citations: 5     Fields:    Translation:Humans
    399. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019 May; 109(5):545-552. PMID: 30830579.
      Citations: 13     Fields:    Translation:Humans
    400. Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ. Treatment of relapsed/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019 Mar; 17(3):166-175. PMID: 30969955.
      Citations: 14     Fields:    Translation:Humans
    401. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 06 01; 125(11):1855-1866. PMID: 30811597.
      Citations: 5     Fields:    Translation:Humans
    402. Tallman MS, Estey EH, Naoe T, Lengfelder E, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Avvisati G, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F, Sanz MA, Fenaux P, L?wenberg B, D?hner H, Ad?s L, Montesinos P. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 04 11; 133(15):1630-1643. PMID: 30803991; PMCID: PMC6509567.
      Citations: 140     Fields:    Translation:Humans
    403. Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019 05 23; 133(21):2348-2351. PMID: 30796023; PMCID: PMC6634962.
      Citations: 13     Fields:    Translation:Humans
    404. Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleva M, Ishizawa J, You MJ, Kantarjian H, Andreeff M, Borthakur G. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. J Clin Invest. 2019 05 01; 129(5):1878-1894. PMID: 30829648; PMCID: PMC6486356.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    405. Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol. 2019; 10:2040620719827310. PMID: 30800259; PMCID: PMC6378516.
      Citations: 32     
    406. Kadia TM, Kantarjian HM, Konopleva M. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. Oncotarget. 2019 Feb 08; 10(12):1250-1265. PMID: 30815228; PMCID: PMC6383813.
      Citations: 6     Fields:    
    407. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019 02; 5(1). PMID: 30709875; PMCID: PMC6371746.
      Citations: 11     Fields:    Translation:Humans
    408. Kantarjian H, O'Brien S. Poor Penetration of Existing Effective Chemoimmunotherapy for the Treatment of Older Patients With Newly Diagnosed Acute Lymphocytic Leukemia (ALL) or Refractory/Relapsed ALL. J Oncol Pract. 2019 02; 15(2):77-79. PMID: 30763202.
      Citations:    Fields:    Translation:Humans
    409. Fredell MN, Kantarjian HM, Shih YT, Ho V, Mukherjee B. How much of US health care spending provides direct care or benefit to patients? Cancer. 2019 05 01; 125(9):1404-1409. PMID: 30695098.
      Citations: 1     Fields:    Translation:Humans
    410. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019 05 15; 125(10):1665-1673. PMID: 30668890.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials <